389 related articles for article (PubMed ID: 31104222)
1. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
[TBL] [Abstract][Full Text] [Related]
2. Integrating Molecular Subclassification of Medulloblastomas into Routine Clinical Practice: A Simplified Approach.
Kaur K; Kakkar A; Kumar A; Mallick S; Julka PK; Gupta D; Suri A; Suri V; Sharma MC; Sarkar C
Brain Pathol; 2016 May; 26(3):334-43. PubMed ID: 26222673
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples.
D'Arcy CE; Nobre LF; Arnaldo A; Ramaswamy V; Taylor MD; Naz-Hazrati L; Hawkins CE
J Neuropathol Exp Neurol; 2020 Apr; 79(4):437-447. PubMed ID: 32053195
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Accuracy of a Reduced Immunohistochemical Panel in Medulloblastoma Molecular Subtyping, Correlated to DNA-methylation Analysis.
Tauziède-Espariat A; Huybrechts S; Indersie E; Dufour C; Puget S; Chivet A; Roux A; Pagès M; Gareton A; Chrétien F; Lechapt E; Ayrault O; Varlet P
Am J Surg Pathol; 2021 Apr; 45(4):558-566. PubMed ID: 33323893
[TBL] [Abstract][Full Text] [Related]
5. Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas.
Kunder R; Jalali R; Sridhar E; Moiyadi A; Goel N; Goel A; Gupta T; Krishnatry R; Kannan S; Kurkure P; Deopujari C; Shetty P; Biyani N; Korshunov A; Pfister SM; Northcott PA; Shirsat NV
Neuro Oncol; 2013 Dec; 15(12):1644-51. PubMed ID: 24203893
[TBL] [Abstract][Full Text] [Related]
6. A simplified approach using Taqman low-density array for medulloblastoma subgrouping.
Cruzeiro GAV; Salomão KB; de Biagi CAO; Baumgartner M; Sturm D; Lira RCP; de Almeida Magalhães T; Baroni Milan M; da Silva Silveira V; Saggioro FP; de Oliveira RS; Dos Santos Klinger PH; Seidinger AL; Yunes JA; de Paula Queiroz RG; Oba-Shinjo SM; Scrideli CA; Nagahashi SMK; Tone LG; Valera ET
Acta Neuropathol Commun; 2019 Mar; 7(1):33. PubMed ID: 30832734
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological characteristics, molecular subgrouping, and expression of miR-379/miR-656 cluster (C14MC) in adult medulloblastomas.
Kaur K; Kakkar A; Kumar A; Purkait S; Mallick S; Suri V; Sharma MC; Julka PK; Gupta D; Suri A; Sarkar C
J Neurooncol; 2016 Dec; 130(3):423-430. PubMed ID: 27576698
[TBL] [Abstract][Full Text] [Related]
8. Molecular subgrouping of medulloblastoma in pediatric population using the NanoString assay and comparison with immunohistochemistry methods.
Kim JW; Park SH; Choi SA; Kim SK; Koh EJ; Won JK; Nam SM; Phi JH
BMC Cancer; 2022 Nov; 22(1):1221. PubMed ID: 36437460
[TBL] [Abstract][Full Text] [Related]
9. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.
Ellison DW; Dalton J; Kocak M; Nicholson SL; Fraga C; Neale G; Kenney AM; Brat DJ; Perry A; Yong WH; Taylor RE; Bailey S; Clifford SC; Gilbertson RJ
Acta Neuropathol; 2011 Mar; 121(3):381-96. PubMed ID: 21267586
[TBL] [Abstract][Full Text] [Related]
10. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
11. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.
Ramaswamy V; Remke M; Bouffet E; Faria CC; Perreault S; Cho YJ; Shih DJ; Luu B; Dubuc AM; Northcott PA; Schüller U; Gururangan S; McLendon R; Bigner D; Fouladi M; Ligon KL; Pomeroy SL; Dunn S; Triscott J; Jabado N; Fontebasso A; Jones DT; Kool M; Karajannis MA; Gardner SL; Zagzag D; Nunes S; Pimentel J; Mora J; Lipp E; Walter AW; Ryzhova M; Zheludkova O; Kumirova E; Alshami J; Croul SE; Rutka JT; Hawkins C; Tabori U; Codispoti KE; Packer RJ; Pfister SM; Korshunov A; Taylor MD
Lancet Oncol; 2013 Nov; 14(12):1200-7. PubMed ID: 24140199
[TBL] [Abstract][Full Text] [Related]
12. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF
PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704
[TBL] [Abstract][Full Text] [Related]
13. Simplified Molecular Subtyping of Medulloblastoma for Reduced Cost and Improved Turnaround Time.
Shuangshoti S; Tadadontip P; Techavichit P; Thorner PS; Shuangshoti S; Teerapakpinyo C
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):538-543. PubMed ID: 31343993
[TBL] [Abstract][Full Text] [Related]
14. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.
Korshunov A; Remke M; Werft W; Benner A; Ryzhova M; Witt H; Sturm D; Wittmann A; Schöttler A; Felsberg J; Reifenberger G; Rutkowski S; Scheurlen W; Kulozik AE; von Deimling A; Lichter P; Pfister SM
J Clin Oncol; 2010 Jun; 28(18):3054-60. PubMed ID: 20479417
[TBL] [Abstract][Full Text] [Related]
15. Nomograms based on preoperative multiparametric magnetic resonance imaging for prediction of molecular subgrouping in medulloblastoma: results from a radiogenomics study of 111 patients.
Dasgupta A; Gupta T; Pungavkar S; Shirsat N; Epari S; Chinnaswamy G; Mahajan A; Janu A; Moiyadi A; Kannan S; Krishnatry R; Sastri GJ; Jalali R
Neuro Oncol; 2019 Jan; 21(1):115-124. PubMed ID: 29846693
[TBL] [Abstract][Full Text] [Related]
16. Reproducibility of the NanoString 22-gene molecular subgroup assay for improved prognostic prediction of medulloblastoma.
Leal LF; Evangelista AF; de Paula FE; Caravina Almeida G; Carloni AC; Saggioro F; Stavale JN; Malheiros SMF; Mançano B; de Oliveira MA; Luu B; Neder L; Taylor MD; Reis RM
Neuropathology; 2018 Oct; 38(5):475-483. PubMed ID: 30155928
[TBL] [Abstract][Full Text] [Related]
17. A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma.
Gómez S; Garrido-Garcia A; Garcia-Gerique L; Lemos I; Suñol M; de Torres C; Kulis M; Pérez-Jaume S; Carcaboso ÁM; Luu B; Kieran MW; Jabado N; Kozlenkov A; Dracheva S; Ramaswamy V; Hovestadt V; Johann P; Jones DTW; Pfister SM; Morales La Madrid A; Cruz O; Taylor MD; Martin-Subero JI; Mora J; Lavarino C
Clin Cancer Res; 2018 Mar; 24(6):1355-1363. PubMed ID: 29351917
[No Abstract] [Full Text] [Related]
18. Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.
Łastowska M; Trubicka J; Niemira M; Paczkowska-Abdulsalam M; Karkucińska-Więckowska A; Kaleta M; Drogosiewicz M; Perek-Polnik M; Krętowski A; Cukrowska B; Grajkowska W; Dembowska-Bagińska B; Matyja E
J Neurooncol; 2018 Jun; 138(2):231-240. PubMed ID: 29427151
[TBL] [Abstract][Full Text] [Related]
19. Proteomic profiling of medulloblastoma reveals novel proteins differentially expressed within each molecular subgroup.
Narayan V; Jaiswal J; Sugur H; Sd S; Rao S; Chatterjee A; Gowda H; A A; Somanna S; Santosh V
Clin Neurol Neurosurg; 2020 Sep; 196():106028. PubMed ID: 32580068
[TBL] [Abstract][Full Text] [Related]
20. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.
Ellison DW; Kocak M; Dalton J; Megahed H; Lusher ME; Ryan SL; Zhao W; Nicholson SL; Taylor RE; Bailey S; Clifford SC
J Clin Oncol; 2011 Apr; 29(11):1400-7. PubMed ID: 20921458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
